Qiming Venture Partners has recorded its fifth IPO within its portfolio since the start of the year, after Alamar Biosciences officially began trading on Nasdaq on April 17.
Founded in 2018, Alamar was established by a team led by scientist and inventor Yuling Luo. The company specializes in femtogram-level, fully automated proteomics platforms, focusing on the development and commercialization of proteomics technologies and aiming to set a high standard in protein detection and analysis.
Alamar’s proprietary Nulisa technology addresses the design limitations of existing proteomics tools. With ultrahigh sensitivity, high specificity, flexible multiplex protein detection capabilities, a wide dynamic range, and a fully automated workflow, it is designed to detect protein biomarkers at extremely low concentrations, targeting a gap not previously addressed by other protein detection methods.
At the same time, Alamar’s proprietary Argo HT is a fully automated, high-throughput instrument that enables a “sample in, results out” workflow, supporting faster market adoption. By the end of 2025, cumulative installations of Argo HT instruments had exceeded 100 units, and the company reported more than 300 customers across 25 countries. Since the commercialization of its platform, more than 100 scientific papers based on its technologies and products have been published.
Notably, Alamar’s patented Nulisa technology, combined with its Argo HT instrument, forms a protein detection solution designed to deliver both sensitivity and breadth. On a single platform, it supports both high-throughput proteomics and targeted protein biomarker detection. With femtogram-level sensitivity, the ability to run hundreds of measurements in parallel, a 12-log dynamic range, a fully automated workflow, and consistent specificity, it is positioned as a platform capable of supporting the full life cycle of protein biomarkers, from discovery and validation to translation.
Since its founding, Alamar has received backing from several notable investors. Qiming led its Series A funding round in 2020 and continued to support the company through its Series B and Series C rounds. Before the IPO, Qiming held an approximately 19.2% stake in Alamar, making it one of the company’s key backers.
This article was adapted based on a feature originally written by and published on IPO Zaozhidao. KrASIA is authorized to translate, adapt, and publish its contents.